However, as compared to CA12, CA9 received more attention for targeted therapy due to its elevated expression in various aggressive tumours with poor clinical outcomes as well as its strong connection with hypoxic tumour microenvironment [18–24,26,32,75]. The gene discussed is CA9; the disease is neoplasm.